Literature DB >> 31416841

ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.

Steffan Vartanian1, James Lee1, Christiaan Klijn2, Florian Gnad2, Maria Bagniewska1, Gabriele Schaefer3, Donglu Zhang4, Jenille Tan1, Sara A Watson1, Liling Liu4, Honglin Chen5, Yuxin Liang5, Colin Watanabe2, Trinna Cuellar5, David Kan3, Ryan J Hartmaier6, Ted Lau1, Michael R Costa1, Scott E Martin1, Mark Merchant3, Benjamin Haley5, David Stokoe7.   

Abstract

Mutations in KEAP1 and NFE2L2 (encoding the protein Nrf2) are prevalent in both adeno and squamous subtypes of non-small cell lung cancer, as well as additional tumor indications. The consequence of these mutations is stabilized Nrf2 and chronic induction of a battery of Nrf2 target genes. We show that knockdown of Nrf2 caused modest growth inhibition of cells growing in two-dimension, which was more pronounced in cell lines expressing mutant KEAP1. In contrast, Nrf2 knockdown caused almost complete regression of established KEAP1-mutant tumors in mice, with little effect on wild-type (WT) KEAP1 tumors. The strong dependency on Nrf2 could be recapitulated in certain anchorage-independent growth environments and was not prevented by excess extracellular glutathione. A CRISPR screen was used to investigate the mechanism(s) underlying this dependence. We identified alternative pathways critical for Nrf2-dependent growth in KEAP1-mutant cell lines, including the redox proteins thioredoxin and peroxiredoxin, as well as the growth factor receptors IGF1R and ERBB3. IGF1R inhibition was effective in KEAP1-mutant cells compared with WT, especially under conditions of anchorage-independent growth. These results point to addiction of KEAP1-mutant tumor cells to Nrf2 and suggest that inhibition of Nrf2 or discrete druggable Nrf2 target genes such as IGF1R could be an effective therapeutic strategy for disabling these tumors. SIGNIFICANCE: This study identifies pathways activated by Nrf2 that are important for the proliferation and tumorigenicity of KEAP1-mutant non-small cell lung cancer. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31416841     DOI: 10.1158/0008-5472.CAN-18-2086

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  CircATP5SL promotes infantile haemangiomas progression via IGF1R regulation by targeting miR-873-5p.

Authors:  Zhiqiang Wei; Xiaoqi Yuan; Qi Ding; Yanan Xu; Lu Hong; Jianhua Wang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.

Authors:  An-Dong Liu; Jie Zhou; Xiao-Yang Bi; Guo-Qing Hou; Shawn Shun-Cheng Li; Qing Chen; Hui Xu; Xuan Cao
Journal:  Clin Transl Med       Date:  2021-03

3.  Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboring KEAP1/NFE2L2.

Authors:  Xiaodong Yang; Ming Li; Zhencong Chen; Xiaobin Fan; Liang Guo; Bo Jin; Yiwei Huang; Qun Wang; Liang Wu; Cheng Zhan
Journal:  J Cancer       Date:  2022-02-28       Impact factor: 4.207

Review 4.  The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context.

Authors:  Faliang Xing; Qiangsheng Hu; Yi Qin; Jin Xu; Bo Zhang; Xianjun Yu; Wei Wang
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.